EnGeneIC said today that the FDA granted orphan drug designation to the company’s targeted EDV nanocells for the treatment of glioblastoma multiforme.
The clinical stage biopharmaceutical company is developing bacterially-derived EDV nanocells as a nanoparticle, siRNA and miRNA delivery platform designed to target and kill tumor cells, while triggering the immune system’s natural anti-tumor response.
Get the full story at our sister site, Drug Delivery Business News.
The post EnGeneIC wins orphan drug designation for targeted nanocells appeared first on MassDevice.